HZNP - Horizon Therapeutics ticks higher amid report FTC meeting unrelated to Amgen deal

2023-05-12 15:56:01 ET

• Horizon Therapeutics ( NASDAQ: HZNP ) rose 1% amid a report that a Federal Trade Commission closed door meeting on Friday is likely unrelated to the Amgen's ( AMGN ) planned acquisition.
• The meeting appears to be unrelated to the transaction, according to traders, who cited a CTFN report that's circulating. The parties believe that the FTC staff has recommended clearance for the deal, though FTC Chair Lina Khan could do a "walk around" vote if she desired.
• The report comes after a Dealreporter item a week ago said that Amgen's ( AMGN ) planned acquisition is expected to close on May 23. Horizon ( HZNP ) employees were told to expect a deal close on May 23.
• Investors are awaiting a May 22 Irish court hearing for Horizon's ( HZNP ) planned $28 billion sale to Amgen ( AMGN ) as well as FTC approval for the deal. Horizon ( HZNP ) and Amgen ( AMGN ) in late January confirmed they received a second request from the FTC.

For further details see: